Details of the Drug
General Information of Drug (ID: DM906JK)
Drug Name |
Pyrrolidine-1-carbonitrile
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Pyrrolidine-1-carbonitrile; 1530-88-7; 1-Pyrrolidinecarbonitrile; 1-Cyanopyrrolidine; N-Cyanopyrrolidine; CHEMBL262697; QJRYYOWARFCJQZ-UHFFFAOYSA-N; pyrrolidinecarbonitrile; cyanopyrrolidine; Cyano-Pyrrolidine; NSC44225; EINECS 216-234-3; Tetramethylenecyanamide; AC1L2KEM; AC1Q4SLA; 1-pyrrolidine carbonitrile; CTK0I1775; DTXSID90165192; MolPort-000-145-877; ZINC1676633; KS-00002AX2; NSC-44225; 4756AD; BDBM50095495; SBB059310; AKOS006227753; MCULE-2010942719; PS-9344; CJ-27397; AN-49391; KB-65041; FT-0607667; ST51044369; P2337; A827637
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 96.13 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||